Enhancing the Oral Bioavailability of Candesartan Cilexetil Loaded Nanostructured Lipid Carriers: In Vitro Characterization and Absorption in Rats after Oral Administration

Enhancing the Oral Bioavailability of Candesartan Cilexetil Loaded Nanostructured Lipid Carriers: In Vitro Characterization and Absorption in Rats after Oral Administration

Candesartan Cilexetil (CC) is a prodrug widely used in the treatment of hypertension and heart failure, but it has some limitations, such as very poor aqueous solubility, high affinity to P-glycoprotein efflux mechanism, and hepatic first-pass metabolism. Therefore, it has very low oral bioavailabil...

Full description

Bibliographic Details
Main Authors:	Walid Anwar, Hamdy M. Dawaba, Mohsen I. Afouna, Ahmed M. Samy, Mohammed H. Rashed, Abdelaziz E. Abdelaziz
Format:	Article
Language:	English
Published:	MDPI AG 2020-10-01
Series:	Pharmaceutics
Subjects:	Candesartan Cilexetil nanostructured lipid carriers oral bioavailability lymphatic transport cellular absorption
Online Access:	https://www.mdpi.com/1999-4923/12/11/1047

Similar Items

Formulation and Bioavailability of Novel Mucoadhesive Buccal Films for Candesartan Cilexetil in Rats
by: Omar Y. Mady, et al.
Published: (2021-08-01)

Repurposing Candesartan Cilexetil as Antibacterial Agent for MRSA Infection
by: Lanlan Xu, et al.
Published: (2021-09-01)

New Peceol™/Span™ 60 Niosomes Coated with Chitosan for Candesartan Cilexetil: Perspective Increase in Absolute Bioavailability in Rats
by: AbuElfadl A, et al.
Published: (2021-08-01)

Oral nanoemulsions of candesartan cilexetil: formulation, characterization and in vitro drug release studies
by: Halah Hussein Ali, et al.
Published: (2017-06-01)

Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool
by: Andrés Figueroa-Campos, et al.
Published: (2020-07-01)

Use of compounded dispersing media for extemporaneous pediatric syrups with candesartan cilexetil and valsartan
by: Musko Monika, et al.
Published: (2014-12-01)

Novel Combination for Self-Nanoemulsifying Drug Delivery System of Candesartan Cilexetil
by: Safa F. Mekhilef, et al.
Published: (2018-12-01)

Response surface based optimization of system variables for liquid chromatographic analysis of candesartan cilexetil
by: Jagdish V. Manwar, et al.
Published: (2017-01-01)

Developing pH-Modulated Spray Dried Amorphous Solid Dispersion of Candesartan Cilexetil with Enhanced In Vitro and In Vivo Performance
by: Surendra Poudel, et al.
Published: (2021-04-01)

Effects of combination of AT1-antagonist candesartan cilexetil and ASE-inhibitors in patients with congestive heart failure
by: Gašanin Edis, et al.
Published: (2013-01-01)

Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T)
by: Bramlage P, et al.
Published: (2011-02-01)

Modelling Drying Time of Candesartan Cilexetil Powder Using Computational Intelligence Technique
by: Sonia Keskes, et al.
Published: (2021-03-01)

Development and validation of a dissolution test with reversed-phase high performance liquid chromatographic analysis for Candesartan cilexetil in tablet dosage forms
by: Vairappan Kamalakkannan, et al.
Published: (2016-09-01)

Differential clinical profile of candesartan compared to other angiotensin receptor blockers
by: Zimlichman R
Published: (2011-12-01)

Preparation of Candesartan and Atorvastatin Nanoparticles by Solvent Evaporation
by: Josef Jampilek, et al.
Published: (2012-11-01)

Candesartan cilexetil in cardiovascular prevention
by: A. Ya. Ivleva
Published: (2007-12-01)

Oral solid self-nanoemulsifying drug delivery systems of candesartan citexetil: formulation, characterization and in vitro drug release studies
by: Halah Hussein Ali, et al.
Published: (2017-06-01)

Oral Bioavailability Enhancement of Raloxifene with Nanostructured Lipid Carriers
by: Aditya Murthy, et al.
Published: (2020-05-01)

Identification of new process-related impurity in the key intermediate in the synthesis of TCV-116
by: Testen Ana, et al.
Published: (2019-03-01)

Improving intestinal absorption and oral bioavailability of curcumin via taurocholic acid-modified nanostructured lipid carriers
by: Tian C, et al.
Published: (2017-10-01)

Pharmacokinetics and Biodistribution of Thymoquinone-loaded Nanostructured Lipid Carrier After Oral and Intravenous Administration into Rats
by: Zakarial Ansar FH, et al.
Published: (2020-10-01)

Solid State Stability and Kinetics of Degradation for Candesartan—Pure Compound and Pharmaceutical Formulation
by: Valentina Buda, et al.
Published: (2020-01-01)

No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects
by: Kim JR, et al.
Published: (2018-08-01)

Selenium-coated nanostructured lipid carriers used for oral delivery of berberine to accomplish a synergic hypoglycemic effect
by: Yin J, et al.
Published: (2017-12-01)

Candesartan in treating hypertension
by: L O Minushkina
Published: (2014-03-01)

Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks
by: Mohammed Elmowafy, et al.
Published: (2017-01-01)

Preparation and characterization of nimodipine-loaded nanostructured lipid systems for enhanced solubility and bioavailability
by: Teng Z, et al.
Published: (2018-12-01)

Formulation design, characterization, and in vitro and in vivo evaluation of nanostructured lipid carriers containing a bile salt for oral delivery of gypenosides
by: Yang G, et al.
Published: (2019-04-01)

Systemic Design and Evaluation of Ticagrelor-Loaded Nanostructured Lipid Carriers for Enhancing Bioavailability and Antiplatelet Activity
by: Gi-Ho Son, et al.
Published: (2019-05-01)

Synthesis of Tilmicosin Nanostructured Lipid Carriers for Improved Oral Delivery in Broilers: Physiochemical Characterization and Cellular Permeation
by: Benazir Sahito, et al.
Published: (2020-01-01)

CANDESARTAN IN CARDIOLOGY PRACTICE
by: N. A. Dzhaiani
Published: (2017-12-01)

Cost Effectiveness Kombinasi Antihipertensi Candesartan-Bisoprolol dan Candesartan-Amlodipin Pada Pasien Rawat Jalan Penderita Hipertensi
by: Eny Nurhikma, et al.
Published: (2019-12-01)

Candesartan in the prevention of cardiovascular catastrophes: emphasis on the pre-vention of stroke
by: Oksana Mikhaylovna Drapkina, et al.
Published: (2009-12-01)

Candesartan effectiveness in essential arterial hypertension and renal arterial hypertension
by: N. M. Chikhladze, et al.
Published: (2008-12-01)

Morphological changes in tissues of organs in rats with arterial hypertension (SHR) with treatment of hypotensive medicines (with ramipril and candesartan) in combination with corvitin
by: Alena Marushchak, et al.
Published: (2020-02-01)

Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism
by: Xinran Wang, et al.
Published: (2021-01-01)

Evaluation of the effectiveness of candesartan, diltiazem, or their combination on normo-, micro- and macroalbuminuria in type 2 diabetic patients
by: Jawad H. Ahmed, et al.
Published: (2013-12-01)

Sartans in hypertension treatment: advantages of candesartan use
by: Marina V. Leonova
Published: (2019-01-01)

The benefits of candesartan usage in the treatment of arterial hypertension
by: O D Ostroumova, et al.
Published: (2014-06-01)

Oral Bioavailability and Lymphatic Transport of Pueraria Flavone-Loaded Self-Emulsifying Drug-Delivery Systems Containing Sodium Taurocholate in Rats
by: Jin Qiao, et al.
Published: (2018-09-01)